AbbVie Inc (NYSE: ABBV) has reported E.P.S. of $0.77 for its first fiscal quarter (ending March 31) versus $0.13 for the same period a year ago — an increase of 492%. Relative to the consensus estimate of $2.77, this was a shortfall of $-2.00. For the latest four quarters through March 31, E.P.S. were $3.37 versus $4.26 for the same period a year ago — a decline of -21%.
Recent Price Action
AbbVie Inc (NYSE: ABBV) stock closed at $159.62 on 4/26/24 after a decline of -4.6%. Moreover, unusually high trading volume at 185% of normal accompanied the decline. The stock has declined -3.1% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ABBV is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
AbbVie has a current Value Trend Rating of C (High Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. AbbVie has a neutral Appreciation Score of 52 and a slightly positive Power Rating of 69, resulting in the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment